Regencell Bioscience Holdings Ltd
Business
Regencell Bioscience Holdings Ltd is a holding company that conducts research, development and commercialization of traditional Chinese medicine (TCM) therapies targeting neurocognitive disorders, specifically ADHD and ASD. It develops personalized and standardized liquid-based TCM formula candidates, conducts efficacy trials, pursues patent and trademark protection, and plans manufacturing and commercialization activities. The company operates through subsidiaries and strategic partnership agreements with a TCM practitioner to manage R&D, clinical trials and intellectual property. Initial research, trials and planned commercialization occur in Hong Kong, with distribution via clinics, proprietary product registration, TCM wholesalers/stores and planned expansion to the U.S. and other international markets.
Summary from filing dated 2025-10-31
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-3.58M |
| Total assets | $5.76M |
| Total liabilities | $895.3K |
| Stockholders' equity | $4.86M |
| Operating cash flow | $-3.11M |